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Abstract
Alzheimer disease (AD) is a neurodegenerative disorder characterized by progressive decline of cognitive function that
represents one of the most dramatic medical challenges for the aging population. Ab peptides, generated by processing of
the Amyloid Precursor Protein (APP), are thought to play a central role in the pathogenesis of AD. However, the network of
physical and functional interactions that may affect their production and deposition is still poorly understood. The use of a
bioinformatic approach based on human/mouse conserved coexpression allowed us to identify a group of genes that
display an expression profile strongly correlated with APP. Among the most prominent candidates, we investigated whether
the collagen chaperone HSP47 could be functionally correlated with APP. We found that HSP47 accumulates in amyloid
deposits of two different mouse models and of some AD patients, is capable to physically interact with APP and can be
relocalized by APP overexpression. Notably, we found that it is possible to reduce the levels of secreted Ab peptides by
reducing the expression of HSP47 or by interfering with its activity via chemical inhibitors. Our data unveil HSP47 as a new
functional interactor of APP and imply it as a potential target for preventing the formation and/or growth amyloid plaques.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disorder, with a prevalence of approximately 2% in
developed countries. The risk of developing this disorder increases
dramatically in individuals beyond the age of 70 and it is predicted
that the incidence of AD will rise threefold within the next 50
years, hence representing an outstanding social problem [1]. From
the neuropathologic point of view, AD is characterized by
progressive loss of neurons and synapses, intracellular neurofibril-
lary tangles composed of hyperphosphorylated Tau protein,
extracellular deposition of b-amyloid substance on senile plaques
(SP) and cerebral amyloid angiopathy [2,3]. The main constituents
of SP are Ab-peptides, which are generated from b-amyloid
precursor protein (APP) by sequential proteolytic cleavages,
mediated by b- and c-secretases. An alternative non-amyloido-
genic a-secretase cleavage cuts APP in the middle of the Abregion
[4,5]. Although APP is a ubiquitous type I transmembrane
glycoprotein [4], alternative splicing can generate at least three
main isoforms, characterized by important differences in their
expression pattern. The short variant, known as APP695, is the
most abundant isoform in mature brain, while longer isoforms,
containing a Kunitz protease inhibitor (KPI) domain, such as the
APP770, are the main variants expressed in the other tissues and
during brain development [6,7]. Nevertheless, KPI-positive APP
isoforms could be important in brain under abnormal conditions,
since their levels are significantly increased after traumatic injury
[8], after seizures [9] and in AD patients [10].
Despite the large body of knowledge accumulated in the last two
decades on APP proteins, some fundamental issues about their
physiological role and about their cleavage pathways remain to be
fully elucidated. However, structural and functional evidences
indicate that APP and APP-like proteins may function as adhesion-
receptors and signal transduction molecules during cell migration
[11–13], neurite outgrowth, dendritic arborization and synapto-
genesis [14–16]. A full definition of the complex network of
physical and functional interactions that involve APP is crucial for
understanding its normal and abnormal functions and for
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identifying novel potential targets for therapeutic intervention.
Although many players have been already identified by biochem-
ical approaches, the picture is probably still very incomplete.
The availability of massive sets of microarray data from
different species offers a unique opportunity to analyze gene
function on a global scale, based on the principle that genes
cooperating to the same biological functions tend to be
significantly coexpressed [17]. In this report, we used a conserved
coexpression approach to identify new putative functional partners
of APP. We defined a gene signature strongly enriched for
molecules previously implicated with APP function and/or with
AD. Among these genes, we concentrated on HSP47, a serine
protein inhibitor (SERPIN) well known for its collagen-chaperone
activity [18]. We found that HSP47 is capable to physically
interact with APP and that its intracellular localization pattern is
sensitive to APP levels. Moreover, we show that HSP47 is enriched
in amyloid plaques, in two different mouse models of AD and in
some AD patients. Finally we show that HSP47 knockdown or
pharmacological inhibition reduces the levels of extracellular Ab
peptides released by cell lines expressing normal or mutant APP,
as well as by primary neuronal cultures. Our results imply that
HSP47 could be a novel target for reducing Ab levels in vivo.
Materials and Methods
Coexpression analysis
The list of mammalian genes showing conserved coexpression
with APP was obtained from the dataset previously described [19],
using essentially the same procedures, with minor modifications.
Briefly, we used all the ratiometric datasets available in the
Stanford Microarray Database (SMD) [20] on 01-01-2004 for
human (2803 experiments, 74588 probes, comprising 6 indepen-
dent APP probes) and for mouse (145 experiments, 37521 probes,
comprising 6 independent APP probes). For every probe, we
calculated the Pearson correlation coefficient (r1) with all other
probes (rx), and ranked the probes according to the values of this
index. A directed edge was established from r1 to rx if rx fell within
the top 1% rows in terms of correlation with r1.
These directed networks were then converted into undirected
networks by mapping the probes to the corresponding Entrez
Gene identifiers. The list of genes whose expression is strictly co-
modulated with APP is defined as the ensemble of the first-level
neighbors. We then searched all the 36 possible combinations of
the obtained single-species lists for the presence of orthologous
genes, defined on the basis of the Homologene database, resulting
in the production of 36 conserved-coexpression lists. The final list
of candidates was obtained by retaining only those genes that were
found in 7 conserved coexpression lists, thus ensuring that they
occurred in at least 2 independent single-species coexpression lists
of each organism. The Gene Ontology keyword overrepresenta-
tion was performed according to standard procedures [21].
Cell culture
HEK293 cells stably expressing human APP carrying the
Swedish mutation [22] (a kind gift from Bart De Strooper,
Katolike Universite Leuven) 293 cells (ATCC) and HeLa cells
(ATCC) were grown in Dulbecco’s modified Eagle’s Medium
(DMEM) supplemented with 10% fetal calf serum (FCS). Sy5y
(ATCC) cells were grown in the same medium plus 5% horse
serum. Hippocampal neuronal cultures were prepared from
embryonic day (E) 18 rat brains as described [23]. Rat primary
cortical neurons cultures were prepared from cortices of E18 rat
brains, using the protocol described in [23] with minor
modifications.
Ethics
The human sections used for this study correspond to autoptic
archive material not subjected to the acquisition of an informed
consent. The ‘‘Centro DOMP’’, that performed the analysis of the
human samples, is a diagnostic structure operating under the
control of the Ethic Committe: ‘‘Comitato Etico dell’ASL-TO2,
Ospedale Maria Vittoria, Torino’’.
For the preparation of primary hippocampal neurons, pregnant
rats and embryos were sacrificed conforming to the Italian laws on
animal experimentation and under the supervision of the
veterinary service of our animal facility. The corresponding
experimental protocols have been approved by the Italian Ministry
of Health, Department of Public Veterinary Health with approval
number 22/2007-A, released on 03/14/2007.
Antibodies
We used the following antibodies: rabbit polyclonal anti-APP C-
term (Sigma); rabbit polyclonal anti-Ab 37–42 (AB5306, Cov-
ance); mouse monoclonal anti-Ab 1–16 (6E10, Covance); mouse
monoclonal anti-HSP47 (Stressgen); rabbit polyclonal anti-Tau
(ab8763 Abcam); goat polyclonal anti-Rpn2 (Santa Cruz biotech-
nology); rabbit polyclonal anti-GFP (Abcam); mouse monoclonal
anti-MYC 9E10 (Sigma); mouse monoclonal anti btubulin
(Sigma); mouse monoclonal anti-Vinculin (Transduction Labora-
tory).
Immunoblotting and immunoprecipitation
Cells were extracted with lysis buffer (1% TritonX-100,
120 mM sodium chloride, 50 mM Tris-HCl pH 7.5), protease
inhibitors mixture (Roche) and 1 mM phenylmethylsulfoniyl
fluoride (PMSF). For the immunoprecipitations (IPs), antibodies
and protein-G-sepharose beads (Amersham, Uppsala, Sweden)
were added to cleared lysates and incubated overnight at 4uC.
Pellets were washed six times with lysis buffer and analysed by
SDS-PAGE. For the immunoblotting, clarified extracts or IPs
were analyzed by reducing SDS-PAGE and transferred to PVDF
filters, which were then incubated with the indicated antibodies
and developed using ECL system (Amersham Biosciences).
In vivo cross-linking
To cross-link physically interacting proteins, cells were first
exposed to DSP (Calbiochem cat#322133) at the concentration of
200 mg/ml in PBS for 10 min at room temperature, then washed
twice with PBS prior to lysis. The lysates were then immunopre-
cipitated using Dynabeads protein G (Invitrogen), according to the
manufacturers’ specifications, with anti-MBP, anti-Hsp47 or anti-
Ab (6E10) monoclonal antibodies.
Immunofluorescence microscopy and
immunohistochemistry
Human sections were obtained from paraffin-embedded blocks
of autoptic material derived from patients initially suspected to
have prion diseases and then diagnosed to be affected by
Alzheimer’s disease or other disorders. Sections from paraffin-
embedded blocks of brain obtained from APPPS1 transgenic mice
and their littermate controls were collected onto collagen coated
slides and stained using the indicated antibodies. Cells and slices
were fixed with 4% paraformaldehyde in PBS and permeabilized
with 0.1% TritonX-100. Immunofluorescence was performed
using the indicated antibodies, followed by incubation with
appropriate Alexa-Conjugated secondary reagents (Molecular
Probes). Nuclei were stained with Hoescht (Sigma). All the
samples were examined using Apotome or confocal imaging
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systems (Zeiss). For immunohistochemistry, all the reactions were
performed on an automated immunostaining system (Leica).
Omission of the primary Ab or substitution with an unrelated
rabbit serum served as negative control.
Real-time analysis of gene expression
6 weeks-old male FVB mice were injected intraperitoneally
using 30 mg/Kg Kainic Acid monohydrated (Sigma) or with same
volume of vehicle only (PBS). Seizures were observed on average
one hour after the injections. 24 hours later the mice were
sacrificed, hippocampi were dissected and total RNA was
extracted using TRIZOL reagent (Invitrogen). Primary rat cortical
neurons were transfected with plasmids or treated with compound
IV. After 72 h from the medium change cells were lysed and total
RNA was extracted using TRIZOL reagent (Invitrogen).
1 mg of total RNA was retrotranscribed to cDNA with random
primers (New England Biolabs) using the M-MLV Reverse
Transcriptase (Invitrogen) according to manufacturer specifica-
tions. Multiplex Real-Time PCR was performed on an AB 7300
station using APPlied Biosystems TaqMan Gene Expression
Assays for the targets Col1a1 (GeneID: 12842), Col6a2 (GeneID:
12834), Col18a1 (GeneID: 12822), mouse HSP47 (GeneID:
12406), rat HSP47 (Gene ID: 29345), Gapdh (Gene ID: 24383),
Itgb1 (GeneID: 16412), Clu (GeneID: 12759), Lrp1 (GeneID:
16971), cav1 (GeneID: 12389), Anxa5 (GeneID: 11747). For
differential expression of APP695 and APP770 we generated
custom differential primers: APP695 Fw=GATGGCGGTGAA-
GACAAAGT; APP695 Rev=CATCAGCTTCCTCTTCCT-
CAA; APP770 Fw=CACCACCACAACCACCACT; APP770
Rev=GGCTTGTTCAGAGCACACCT.
Real Time analysis were performed using eukaryotic 18S rRNA
(APPlied Biosystems, 4319413E) for mouse samples and Gapdh for
rat derived coltures as endogenous control to normalize targets
expression level. Relative quantification of gene expression level
was obtained using the SDS RQ Study software (Applied
Biosystems). All the experiments were performed according to
standard guidelines for use of research animals.
Transfections, RNAi and treatment with the HSP47
inhibitor
For cell lines, cells were plated at a density of 105 cells per well
in a 24 well plate and transfected using Fugene (Mirus) or
Effectene Transfection Reagent (Qiagen) for HeLa or for APPsw
cells, respectively, according to the manufacturers’ specifications.
Rat primary cortical neurons were electroporated before plating
using Amaxa Rat Neuron Nucleofector Kit (Lonza), according to
the manufacturers’ specifications, and plated at a density of 2*106
in 3 cm dishes.
The lentiviral shRNA constructs were obtained by Open
Biosystems (RHS1764-9691844=anti-HSP47; RHS1764-9700081
=control). shRNA constructs for the nucleofection of cortical
neurons were obtained by Open Biosystems (TRCN0000008532
=Mismatched control, RCN0000008531=R1, TRCN0000008534
=R2).
The HSP47 construct was obtained by cloning in the pcDNA
plasmid (Invitrogen) the mouse HSP47 sequence (GeneBank:
NM_009825.2), obtained by RT-PCR. A MYC epitope tag was
inserted before the RDEL sequence. The YFP-APP expression
plasmid was previously described (Kaether et al 2000).
The HSP47 inhibitor compound IV was obtained from
Calbiochem (code 385874). Compounds I and III were obtained
from Ryan Scientific (codes RH01393 and RF03420, respectively).
In most cases cells were incubated with the inhibitor for 24 hours.
Longer incubation times were used for Sy5y (48 hours) cells and
for cortical neurons (72 hours).
ELISA analysis of Ab40 and Ab42 levels and cell vitality
For cell lines producing wild type and/or mutated human APP,
cells were plated at a density of 100000 cells per well in a 24 well
plate. After the indicated treatments and times, the incubation
supernatants were collected and analyzed using an Ab40/42 High
Sensitivity Kit (The Genetic Company) according to the
manufacturer’s specifications. Primary rat cortical neurons were
plated at a density of 2*106 cells in 3 cm diameter dishes. After the
indicated treatments and times, the incubation supernatants were
collected and analyzed using an Human/Rat bAmyloid (40) Elisa
Kit Wako II (Wako), according to the manufacturer’s specifica-
tions. Cells vitality was measured by Crystal Violet staining [24].
To analyze Intracellular Ab, after the collection of the
supernatant, APPsw cells were washed twice, harvested in ice
cold PBS, and centrifuged. Pellets were lysed with lysis buffer (1%
TritonX-100, 120 mM sodium chloride, 50 mM Tris-HCl
pH 7.5), protease inhibitors mixture (Roche) and 1 mM phenyl-
methylsulfoniyl fluoride (PMSF). The resulting lysate was centri-
fuged for 10 min and then the supernatant was collected and
assayed for Aß as specified above.
Statistical Analysis
All experiments were performed on a minimum of three
replicates. Data are shown as mean plus standard deviation and
statistical assessment of the differences was performed using 2-
tailed Student’s t test.
Results
Identification of new potential partners of APP by
conserved coexpression analysis
To obtain more insight about the physiological functions of APP
and to provide a high-confidence group of new possible functional
partners for this protein, we resorted to a conserved-coexpression
approach [19]. To this aim, we analyzed all the available human
and mouse microarray experiments deposited in the SMD, which
included data from 6 human and 6 mouse independent APP
probes, covering partially overlapping sets of experimental
conditions. For every probe, we generated a ranked list of genes
showing the highest coexpression with APP, as previously
described [19]. We then performed pair-wise comparisons of the
entire human and mouse results, obtaining 36 conserved-
coexpression lists. The final list of candidate APP partners (Table
S1, 137 genes) was obtained by selecting only the genes found in at
least two independent APP coexpression lists from each organism.
Since the identification of our candidates was completely
independent from a priori knowledge on APP or AD, to validate
our approach we evaluated how many candidates were already
linked to APP and/or AD by experimental evidence. Interestingly,
for 36 candidates (.25%) it was possible to find at least one
PubMed abstract in which such relationship was established
(Table S1). In particular, 13 genes encode for modulators of APP
metabolism or Ab deposition, 12 are overexpressed in AD or
encode for proteins enriched in AD lesions, 9 are known mediators
of APP- and/or Ab-induced downstream effects, 2 encode for
proteins that colocalize with APP or affect its localization (see
details in Table S1). Notably, the most well characterized partners
and modulators of APP were not detected at the very stringent
cutoff that we used. However, we found that Nicastrin (present in
3 lists), BRI2 (2 lists), FE65 (2 lists) and BACE1 (1 list), display a
significant conserved coexpression with APP. To obtain a more
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systematic validation, we asked whether the candidates were
significantly enriched for previously identified APP-binding
proteins. Strikingly, we found that 10 of them were contained in
the list of 104 APP interactors reported by the Human Protein
Reference Database (HPRD) [25] (p = 6.2?E-9, exact Fisher test).
Moreover, 7 of them had been genetically associated to AD, as
deduced by the Alzgene database [26].
Since it has been previously shown that genes characterized by
strongly conserved coexpression display very similar functional
properties [17], we performed a systematic analysis of the
functional annotation of our candidates, according to the Gene
Ontology (GO) vocabulary [27]. The keywords displaying the
most significant enrichment (Table 1) are fully consistent with the
reported functions of APP. Indeed, they independently support the
idea that APP plays a prominent role in cell-to-matrix interaction
[11], in calcium homeostasis [28], in cell survival [29] and in
neurogenesis [30].
The keywords showing the most striking enrichment were
related to collagen biogenesis. This result is particularly interest-
ing, because APP can physically interact with many different
collagen chains [31–33] and because collagen XVIII [34] and
fragments of collagen XXV [33] have been previously found in
amyloid plaques. Therefore, the result of our bioinformatic screen
suggests the interesting possibility that APP, or at least one of its
isoforms, could be part of a transcriptional module activated in the
central nervous system (CNS) only under specific conditions.
Since the gene expression dataset that we used for our screen
does not contain many CNS-derived samples [19], to directly
validate in the mammalian brain the coexpression between APP
isoforms and the identified collagen-related proteins, we resorted
to a mouse model of kainate-induced seizures [9]. Indeed, it has
been shown that in this model KPI-positive isoforms of APP are
induced, while APP695 levels are not affected [9].
We probed by real time RT-PCR the expression of three
collagen chains and of HSP47, which is known to affect the
maturation of many collagens by its chaperone activity [18].
Moreover, we tested some of the molecules previously correlated
with APP or Aband identified also by our screen.
As expected, the hippocampus of treated mice showed a
significant induction of APP770 mRNA, versus stable levels of the
APP695 isoform (Fig. 1). Interestingly, most of the analyzed genes
were positively regulated in this setting, with HSP47 showing the
highest induction.
These results confirm that, although our original screen was
performed on microarray experiments not derived from the CNS,
many of the candidates may be co-regulated with KPI-positive
isoforms of APP in the adult brain.
Physical interaction and colocalization between HSP47
and APP
Among the many potential new APP partners identified by our
bioinformatic survey, HSP47 emerged as an outstanding candi-
date for experimental validation, not only on the basis of its
collagen-folder activity and co-induction with APP770 after
seizures, but also because it has been previously involved in the
ER stress response [35], which may play an important role in
modulating Abproduction [36]. Therefore, we asked whether
HSP47 is capable to associate with APP in intact cells. To address
this point we first resorted to co-immunoprecipitation assays
between epitope tagged proteins, overexpressed in 293T cells. We
found that, under these conditions, YFP-tagged APP was
specifically associated with overexpressed HSP47 (Fig. S1A).
Interestingly, immunofluorescence studies performed in HeLa
cells showed that APP overexpression can dramatically affect the
intracellular localization of endogenous HSP47, which was
recruited to YFP-APP-positive structures in ,50% of the
transfected cells (Fig. 2A).
To address whether this interaction may occur in a more
physiological context, we tried to co-immunoprecipitate the
endogenous proteins from untransfected HeLa cells. However,
although this cell line expresses robust levels of both HSP47 and
APP, the two proteins could not be immunoprecipitated under
standard conditions. A possible explanation for this discrepancy
could be that the interaction between HSP47 and APP might
occurr very transiently, as it is the case for many chaperone
interactions, which can be detected only after chemical cross-
linking [37]. Accordingly, a specific complex between HSP47 and
APP was specifically immunoprecipitated from HeLa cells after
treatment with the reversible crosslinker DSP [37] (Fig. S1B).
Even more importantly, using the same crosslinking protocol,
the complex was immunoprecipitated also from cultured primary
cortical neurons, both with anti-HSP 47 and with anti APP
antibodies, but not with an unrelated antibody (Fig. 2B).
To address whether the two endogenous proteins can be found
in the same cellular compartment in a physiological context, we
resorted to primary rat hippocampal neurons in culture. HSP47
was clearly detectable by western blotting at all stages of the in
vitro differentiation program, with a peak at 14 days in vitro (DIV
- Fig. S2A), a point that in this system [38] corresponds to the
beginning of synaptogenesis. Accordingly, HSP47 was also
detected by immunofluorescence in both undifferentiated (data
not shown) and differentiated neurons (Fig. S2B), in which it
displayed a punctuate localization pattern. In agreement with the
literature, this signal strongly colocalized with the rough ER
marker Ribophorin II ([35], Fig. S2C), thus confirming its
specificity.
Interestingly, co-staining with antibodies recognizing the C-
terminal region of APP revealed that, although the two proteins
tend to be in separate compartments, they are very often
juxtaposed and in some cases clearly colocalized (Fig. 2C).
HSP47 is enriched in amyloid plaques
We then asked whether the expression and/or distribution of
HSP47 are altered in presence of abnormal APP cleavage. To this
aim, we analysed 12-month-old APPPS1 mice, which co-express
Table 1. Gene ontology annotation of the candidate APP
partners.
GO-keyword Number Percentage
Nominal
p-value
Collagen 8 5.80 2.63E-10
Extracellular matrix 15 10.87 5.37E-09
Cell adhesion 20 14.49 7.13E-08
Calcium ion binding 22 15.94 8.31E-08
Apoptosis 18 13.04 8.50E-06
Integrin-mediated signaling pathway 6 4.35 3.21E-06
Neurogenesis 10 7.25 1.46E-05
Analysis of the GO functional annotation of the 137 candidate APP partners
identified by human/mouse conserved coexpression analysis of the SMD. The
reported keywords displayed statistically significant enrichment even after
considering multiple testing (Benjamini correction, corrected p-value,0.01).The
number and the percentage of genes annotated to the corresponding keyword
are indicated.
doi:10.1371/journal.pone.0022370.t001
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KM670/671NL mutated amyloid precursor protein and L166P
mutated Presenilin 1 under the control of the neuron-specific
Thy1 promoter [39]. APPPS1 mice show dramatic deposition of
Ab starting at 6–8 weeks in the neocortex, becoming widespread
in the whole CNS at 8 months ([39] and Fig. 3A). These Ab
deposits appear both as small, congophilic dense-core amyloid
plaques and as diffuse plaques. By immunohistochemistry, we
detected high levels of HSP47 in the blood vessels and in the
choroid plexus of both control and APPPS1 brains (data not
shown), as expected from the literature [40]. However, in addition
to the vascular positivity, APPPS1 mice showed a clear signal in
amyloid plaques (Fig. 3A). Interestingly, this positivity was already
detectable in the small plaques of young mice (Fig. S3), thus
suggesting that HSP47 deposition occurs throughout the process of
plaques formation, starting from its earliest stages. No enrichment
was detected under the same conditions using antibodies
recognizing BiP, a well established marker of the ER (Fig. S4).
Double immunostaining showed that HSP47 is enriched in all
types of amyloid deposits, with a peculiar distribution compared to
that of Ab. In particular, in plaques formed by diffuse Ab
deposition, HSP47 and Ab immunostaining showed the same
overall distribution and a very high degree of colocalization
(Fig. 3B). Moreover, in dense core plaques, anti-HSP47 antibodies
stained the amyloid core, overlapping with anti-Ab staining, but
showed also a distinct punctuate pattern in an Ab-negative region
surrounding the core, that has been previously shown to contain
dystrophic neurites [39]. Accordingly, these areas were specifically
labeled by anti-Tau and anti-APP antibodies, whose signals
significantly overlapped with the HSP47 staining (Fig. 3C–D). A
similar HSP47 enrichment was clearly detectable by immunohis-
tochemistry in the amyloid plaques produced by 36Tg-AD
transgenic mice [41], a second well-studied model of AD
characterized by much less pronounced amyloidosis. This finding
excluded the possibility that the results obtained with APPPS1
mice might be a non-specific effect of the dramatically increased
Ab levels that characterize this particular transgenic line. By
western blot analysis, we could not detect significant differences in
the total levels of HSP47 in APPPS1 mice versus controls (data not
shown), most likely because of the relatively stronger vascular
expression of the protein. To evaluate whether the HSP47
enrichment detected in the mouse models could be relevant to
human AD pathology, we analyzed by immunofluorescence
microscopy brain sections from four AD patients, including one
Braak & Braak [42] stage V–VI case and three III–IV stage cases,
alongside two normal controls. As expected, in the normal samples
HSP47 positivity was mainly restricted to vascular structures
(Fig. 4A). A similar pattern was observed in two of the III–IV stage
patients, which did not show any HSP47 enrichment in amyloid
plaques (data not shown). Interestingly, in the two remaining
patients, a clear positivity was detected in some of the diffuse
amyloid plaques and in the majority of the dense core plaques
(Fig. 4B). Remarkably, in the positive plaques, the distribution of
HSP47 and its colocalizazion with Ab (Fig. 4C–D) were essentially
identical to those observed in APPPS1 mice (Fig. 3). Altogether,
the above results indicate that HSP47 may be a novel component
of AD-related amyloid plaques.
HSP47 modulates the levels of extracellular Ab peptides
The presence of HSP47 in amyloid deposits could be related to
a role of this protein in amyloidogenic cleavage of APP and/or in
the deposition of Ab or it could simply reflect a secondary,
bystander involvement. To discriminate between these possibil-
ities, we decided to address whether HSP47 may modulate the
levels of Ab peptides in cellular models. We first performed
HSP47 RNAi in the 293 APPsw cell line, which expresses a
human APP gene carrying the Swedish mutation and produces
high amount of Abpeptides [22]. We found two independent
siRNA sequences capable of reducing HSP47 protein levels by
approximately 50% (Fig. 5A). Interestingly, both siRNAs
determined a significant reduction of secreted Ab-40 and Ab-42
peptides, if compared to a mismatch control (Fig. 5A). Since we
could not obtain a better knockdown of HSP47 by siRNA
transfection, to reduce more dramatically HSP47 levels we
resorted to miRNA-based lentiviral vectors [43]. After selection,
Figure 1. Gene signature validation in a kainate-induced seizure mouse model. 8-months old mice were treated with vehicle only (Ctr) or
30 mg/kg kainate (Kai). 24 hours after treatment, total RNA was extracted from hippocampi and subjected to real-time RT-PCR using primers specific
for each of the indicated genes. Values were normalized to 18S gene expression and expressed as relative quantity (RQ) of the controls. * = p,0.05;
** = p,0.01 (two tails Student T-Test).
doi:10.1371/journal.pone.0022370.g001
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the cells transduced with an anti-HSP47 construct displayed a
90% reduction of protein levels, compared to cells infected with a
control construct (Fig. 5B). Importantly, if compared to control
cells, the levels of Ab-40 and Ab-42 peptides measurable in the
conditioned medium of the HSP47 knockdown cells displayed a
dramatic reduction, much more pronounced than the reduction
obtained upon transient silencing (Fig. 5B). In both transiently
and stably HSP47-interfered cells, APP protein levels were not
affected (Fig. 5A and 5B). In addition, differently from
extracellular Ab, the levels of intracellular Abdid not change
significantly upon HSP47 RNAi (Fig. 5C). A significant reduction
of Abpeptides was also observed in HeLa cells upon transient
knockdown (Fig. S5), thus excluding the possibility that the effects
observed in 293sw cells are due to APP overexpression and/or to
the presence of a mutated APP sequence. To address whether
HSP47 may affect extracellular Ab levels in a more physiological
context, we performed a knockdown experiment in rat primary
cortical neurons, by transfecting shRNA plasmids. Even in this
case, in cells transfected with plasmids capable of reducing
HSP47 mRNA levels, we observed a strong reduction of Ab-40
levels (Fig. 5D).
Chemical inhibitors of HSP47 decrease the levels of
secreted Ab peptides
Chemical inhibitors of HSP47 have been previously devel-
oped, as lead compounds potentially useful for controlling
fibrosis and metastasis [44]. Therefore, in light of the above
results, we wondered whether the levels of Ab peptides in the
conditioned medium could be inhibited not only by decreasing
HSP47 levels, but also by modulating its biochemical activity.
To address this point, we treated APPsw cells with three
previously described HSP47 inhibitors [44], which are capable
to affect its collagen-folding ability at low-micromolar concen-
trations. The HSP47 inhibitors had no detrimental effects on
cell viability at concentrations as high as 100 mM (data not
shown). Interestingly, all three compounds decreased the levels
of Ab peptides in the conditioned medium, in a dose-dependent
manner (Fig. 6A). The molecule referred as compound IV
displayed the most striking effect, because it reduced Ab
peptides by ,90% at a 15 mM concentration (Fig. 6A). Similar
effects were observed also in HeLa cells (Fig. S6), in Sy5y cells
(Fig. S6) and, most importantly, in rat primary cortical neurons
(Fig. 6B).
Figure 2. APP physically interacts with Hsp47 and affects its intracellular localization. (A) Recruitment of endogenous HSP47 by
overexpressed APP. HeLa cells were transfected with YFP –APP and HSP47 detected by a specific anti-HSP47 antibody. Arrows indicate some of the
intracellular structures showing an obvious colocalization. (B) Primary rat cortical neurons (4 DIV) were exposed to DSP cross linking agent and total
cell lysates were immunoprecipitated with control (MBP), with anti-HSP47 or anti-APP (6E10) antibodies. The immunoprecipitates and 40 mg of the
total lysate were then immunoblotted with anti APP (C-Term) or with anti HSP47. (C) Colocalization of HSP47 and APP in 14 DIV neurons. A high
magnification field of dendrites is shown in the right panel. The signals were in general justaxposed (white arrows) and in some cases were
colocalized (yellow arrows).
doi:10.1371/journal.pone.0022370.g002
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Since the HSP47 inhibitors act most likely by non-covalent
binding [44] we reasoned that, if these effects were specific, they
should be overcome by increasing HSP47 levels. Therefore, we
measured the amount of Ab peptides in the conditioned medium
of 293sw cells transfected with an HSP47 expression construct or
with a control vector, after treatment with vehicle only or with the
Compound IV (7.5 mM). Interestingly, in cells overexpressing
HSP47, the levels of Ab40 were similar to the levels detected in
non-tranfected cells, while Ab42 levels were significantly increased
(Fig. 6C). More importantly, in transfected cells, the levels of both
peptides were not significantly affected by treatment with the
compound IV (Fig. 6C). Altogether, these results indicate that
HSP47 levels and activity can profoundly modify the amount of
secreted Abpeptides.
Discussion
Most of the efforts that have been so far devoted to the
identification of molecules that may affect AD pathogenesis by
functionally interacting with APP were based on biochemical
strategies or on genetic approaches [5]. In this study we have
pursued a similar objective, using a completely different method.
Our approach was based on the assumption that some of the
functional APP partners may share with this molecule a very
Figure 3. Hsp47 deposition in amyloid plaques of AD mouse models. (A) Immunohistochemical analysis of Ab and HSP47 on wild type (WT)
and APPPS1 transgenic mice (12 months old). Arrows indicate HSP47 positive plaques. (B–C) Double immunostaining of APPPS1 brain slices with
HSP47 and Ab antibodies. The diffuse plaques (B) show a marked colocalization of the two signals. In dense core plaques (C), the HSP47 antibody
stained the Ab core and a surrounding coronal area. (D–E) Dense core plaques double-stained with HSP47 and Tau (D) or APP C-terminal (E)
antibodies.
doi:10.1371/journal.pone.0022370.g003
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similar mRNA expression profile. On this basis, we performed a
systematic search for genes that display an expression profile
strongly similar to APP in both human and mouse, taking
advantage of the shear amount of microarray data available for
both organisms. This procedure led to the identification of 137
candidate genes. Considering that the majority of the experiments
that compose the starting dataset are not derived from CNS
samples [19], it could be argued that our candidates are not very
likely to functionally interact with APP in brain or to play any role
in Ab deposition. This view would be consistent with the fact that
a large percentage of the candidates are known to be expressed at
very low levels in brain. Moreover, many of the most intensely
studied physical and functional interactors of APP were not
present in the list. Nevertheless, our approach is validated by the
fact that more than 25% of the candidates were already linked in
some way to APP or AD. In addition, we found evidence that also
BACE1, Nicastrin, BRI2 and Fe65 are significantly coexpressed
with APP, although this becomes evident only by slightly relaxing
the inclusion cutoff. Even more strikingly, the functional
annotation of the candidates is completely consistent with the
available knowledge on APP, further underscoring its role in
processes involving cell-to-extracellular matrix interaction. There-
fore, considering that our approach is completely independent
from previous literature, it is very likely that many of the new
candidates will turn out to be actual functional interactors of APP.
The analysis of an experimental model of epilepsy confirmed
that the coexpression between APP and many of the candidates
can be detected also in CNS tissues. Moreover, this analysis
suggested that, in the CNS, the expression of our candidates may
correlate more with KPI-positive isoforms of APP than with the
APP695 isoform. This scenario could be very significant for AD,
since stressful conditions [45,46] and the KPI-positive isoforms
[10,15,47] have been positively correlated with Ab deposition.
Under this perspective, we think that collagens and molecules
implicated in collagen biogenesis are extremely interesting
candidates. Indeed, collagens are the most enriched protein family
in our list (Table 1). In addition, it was previously shown that APP
can directly bind many different collagen chains [31–33].
Moreover, the deposition of different collagen types has been
documented in epileptic brains [48] and in AD amyloid plaques
[33,34]. On this basis, but also considering its striking upregulation
in the kainate-induced seizure model and its localization to the
ER, we thought to address the possibility that HSP47, a master
player in collagen biogenesis, might be related to APP in an AD-
related context.
The first relevant finding in this direction is that HSP47 is
enriched in amyloid plaques of APPPS1 [39] and of 36Tg-AD
[41] transgenic mice. Indeed, while the expression of HSP47 was
very low in the parenchyma of control brains, it was easily
detectable in amyloid plaques of both models, especially after
formic acid pre-treatment of the sections. Importantly, we were
able to detect a similar enrichment in the diffuse and dense-core
plaques of some AD cases in advanced stages. Although more
studies are clearly necessary to reach statistically significant
conclusions on this point, the latter result suggests that HSP47
could be involved in amyloid deposition in a subset of AD patients.
Thus, it will be very interesting to deeply investigate whether
HSP47 enrichment correlates with some specific clinical features
and/or with disease stage.
We cannot yet reach definitive conclusions about the source of
the HSP47 protein deposited in amyloid plaques. The fact that we
did not observe significant increase of the total amount of HSP47
Figure 4. Hsp47 is enriched in amyloid plaques of AD patients. (A) Immunofluorescence analysis of HSP47 distribution (green) in normal
human brain (Ctr). The arrowhead indicates a positive vessel. (B) Analysis of the distribution of HSP47 (green) and Ab (red) in one of the III–IV stage
AD cases. Arrows indicate two HSP47-positive amyloid plaques. (C–D) High magnification fields of AD brain sections analyzed as in B, showing diffuse
(C) and dense-core (D) HSP47-positive plaques.
doi:10.1371/journal.pone.0022370.g004
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would seem to exclude a mechanism based on increased
expression. However, it is still possible that the deposition is due
to locally increased expression, which would be hard to detect over
the predominant pool of HSP47 coming from blood vessels.
Alternatively, the high local concentration of HSP47 in plaques
could derive exclusively from a local redistribution of the protein.
In both cases, it is possible that some of the deposited HSP47
derives from neuronal cells. Indeed, primary neurons in culture
express significant levels of HSP47, showing the expected
subcellular distribution and a low but significant degree of
Figure 5. HSP47 modulates the levels of extracellular Abeta peptides. (A) APPsw cells were transiently transfected with two independent
siRNA oligonucleotides (H2 and H3) designed against the human HSP47 sequence or with a mismatch control (C1). After additional 36 h in culture,
total cell lysates were analyzed by western blotting (upper panel) with anti HSP47, APP and Vinculin (Vinc) antibodies. In parallel, the amount of Ab
peptide species was determined in the conditioned medium by ELISA (lower panel). (B) APPsw were infected with miRNA-based RNAi lentiviral
vectors directed towards HSP47 or towards an unrelated sequence (RNAi Ctr), expressing also a GFP protein. Polyclonal populations were then
analyzed as in (A) 36 h after the last medium change. (C) Extracellular (E-Ab) and intracellular (I-Ab) Ab peptides were measured separately in APPsw
cells treated as in panel A. (D) Primary rat cortical neurons were electroporated with two indipendent plKO plasmids (R1 and R2) encoding for shRNAs
directed towards HSP47 or with a plKO containing a mismatched sequence (Ctr). 48 h after electroporation medium was changed and, after
additional 72 hours, RNA was exctracted to evaluate Hsp47 knockdown by a Real Time PCR assay. In parallel, the amount of Ab40 in the conditioned
medium was determined by an ELISA assay directed against rodent Ab40 (WAKO). ** = p,0.01; *** = p,0.001 (two tails Student T-Test).
doi:10.1371/journal.pone.0022370.g005
Figure 6. Chemical inhibition of HSP47 decreases the levels of extracellular Abeta peptides. (A) Dose dependent reduction of Ab
peptides levels by increasing concentrations of HSP47 inhibitors in 293 APPsw cells. The amount of Ab peptides species in the conditioned medium
of cells treated with the indicated inhibitors was determined by ELISA 24 hours after the last medium change and expressed as ratio on the vehicle
control. (B) Primary rat cortical neurons were treated 24 h after plating with Compound IV (7.5 bmM) or Vehicle (DMSO). The amount of Ab40 in
conditioned medium was then evaluated as in Fig. 5C. (C) 293 APPsw cells were transiently transfected with an unrelated control plasmid (Mock) or
with an HSP47 overexpression construct. 12 hours later, cells were treated with vehicle only or with 7.5 mM Compound IV (IV). The amount of Ab
peptides in the conditioned medium was determined after additional 24 hours as in (A). ** = p,0.01 (two tails Student T-Test).
doi:10.1371/journal.pone.0022370.g006
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colocalization with APP (Fig. 2C). Moreover, we clearly detected
HSP47 in a region of the dense-core plaques that is characterized
by the presence of dystrophic neurites, as demonstrated by
increased tau deposition. The latter observation suggests that the
levels of HSP47 could be locally increased in regions undergoing
pathologic remodelling. This scenario is supported by the findings
that APP physically interacts with HSP47 (Fig. 2B and S1) and
that endogenous HSP47 can be recruited to intracellular
compartments overexpressing APP (Fig. 2A).
Our in vitro experiments on cultured cells provide direct proof
of concept that HSP47 could play a role in the extracellular
accumulation of Abpeptides. Indeed, in primary rat cortical
neurons, in cells expressing normal levels of wild type APP and in
cells overexpressing mutant APP, the levels of Ab peptides in the
conditioned medium were consistently reduced after HSP47
knockdown. Most likely, this effect is not due to a modulation of
the APP amyloidogenic cleavage. Indeed, total APP levels were
normal by western blotting. Moreover, only the levels of
extracellular Ab are decreased by HSP47 knockdown. On the
basis of these results, the most likely working hypotheses are that
HSP47 could affect the degradation or the solubility of Abpeptides
in the extracellular milieu. On the first line, we find very
interesting that HSP47 is a predicted serine proteinase inhibitor.
As such, it could interfere with the degradation of Abmediated by
plasmin [49] or by other proteases, such as the heat shock protein
Omi, which can preferentially bind and destroy oligomeric Ab
[50].
On the other hand, a conceivable scenario is that HSP47
could influence the described interaction between APP and
collagens or between Ab peptides and collagens [31–33]. By
doing so, it could modulate the deposition of an insoluble matrix
containing both collagen and APP degradation products, which
could also explain the enrichment detected in amyloid plaques.
The finding that small molecules affecting the collagen
chaperone capability of HSP47 can decrease the levels of
extracellular Ab peptides, an activity that can be rescued by
HSP47 overexpression, suggests that the action of HSP47 could
be actually related to collagen production. However, we cannot
exclude that HSP47 may act more directly and that the
inhibitors may influence an alternative activity of the protein,
not impinging on collagen folding.
The latter hypothesis would be supported by the poor
correlation between the activity of the tested molecules versus
collagen-folding and their Ab-reducing capability (compare Fig. 6
with [44]), even though many other factors may explain this
discrepancy.
In conclusion, although much more detailed work is necessary
to dissect these potential mechanisms and to analyze their possible
role in plaque formation, we propose that the modulation of
HSP47 activity, through small molecules, could be a novel
approach to modulate in vivo the levels of soluble Abpeptides.
Supporting Information
Figure S1 Coimmunoprecipitation of overexpressed
and endogenous APP and HSP47 in cell lines. (A) Co-
immunoprecipitation of APP and HSP47. Total cell lysates from
HEK293T cells either untransfected (Mock) or co-transfected with
YFP-APP695 and with MYC-HSP47 or an unrelated control
(MYC-CITDN) were immunoprecipitated with anti-MYC anti-
bodies and analyzed by immunoblotting with anti GFP (upper
panel). The expression of recombinant proteins in the lysate was
verified by immunoblotting, as indicated (middle and lower
panels). (B) HeLa cells were exposed to DSP cross linking agent
and total cell lysates were immunoprecipitated with control (MBP)
or anti-HSP47 antibodies. The immunoprecipitates and 40 mg of
the total lysate were then immunoblotted with anti APP (C-Term)
or with anti HSP47.
(TIF)
Figure S2 Expression of Hsp47 in primary hippocampal
neurons. (A) Total cell lysates (20 mg) of hippocampal neurons
kept in culture for the indicated time (DIV=days in vitro) were
analyzed by western blotting with anti-HSP47 antibodies. Beta-
tubulin (btub) antibodies were used as internal loading control. (B)
Immunofluorescence analysis of HSP47 on 14 DIV primary
hippocampal neurons. Note the punctuate staining pattern. (C)
Colocalization of HSP47 and the rough-ER marker Ribophorin-II
(Rpn2) in 14 DIV neurons. A high magnification field of dendrites
is shown in the right panel. Arrows indicate some points of
colocalization.
(TIF)
Figure S3 Time course analysis of the Hsp47 deposition
in amyloid plaques of AD mose models. Hsp47 deposition
in amyloid plaques is an early event occurring in two different AD
mouse models. (A–C) Serial thin sections of the cortex of APPPS1
mice at 3 (A), 9 (B) and 12 months of age were stained for Hsp47
and Ab. (D) Serial thin sections of 12 months-old 36Tg-AD
mouse brains were stained as above. Note that, in this model, the
number of plaques was much lower than in APPPS1 mice of
comparable age. The white arrow indicates a positive plaque.
Scale bars: 200 mm (A–C); 100 mm (D).
(TIF)
Figure S4 Specificity of HSP47 antibody staining in
amyloid plaques of AD APPPS1 mouse model. Specificity
of Hsp47 enrichment in amyloid plaques of APPPS1 mice.
Immunohistochemistry of cortical serial sections of 9 months old
APPPS1 mice, performed with the indicated primary antibodies
and with the same secondary reagents. The HSP47- positive
amyloid plaques indicated by arrows are not detected by anti BiP
antibodies.
(TIF)
Figure S5 Lowering of Hsp47 in HeLa cells decreases
the levels of extracellular Abeta peptides. HeLa cells were
transiently transfected with two independent siRNA oligonucleo-
tides (h2 and h3) designed against the human HSP47 sequence or
with a mismatch control (r1). After additional 36 h in culture cell
viability was determined the amount of Ab peptide species in the
conditioned medium was determined by ELISA. Values are
expressed as ration on the control. * = p,0.05; ** = p,0.01 (two
tails Student T-Test).
(TIF)
Figure S6 Chemical inhibition of Hsp47 in HeLa cells
and Sy5y cells decreases the levels of extracellular Abeta
peptides. HeLa or Sy5y cells were treated with vehicle only or
with 7.5 mM Compound IV for 24 or 48 hours, respectively. The
concentration of Ab peptides in the conditioned medium was then
determined by ELISA analysis and reported as ratio on the
control. * = p,0.05; ** = p,0.01; *** = p,0.001 (two tails
Student T-Test).
(TIF)
Table S1 List of candidate APP partners identified by
the coexpression-based bioinformatic screen. List of the
137 candidates identified by conserved coexpression analysis on
the SMD dataset. A= colocalized with APP or affecting APP
localization; B= overexpressed in AD or found in AD lesions;
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C=modulator of APP metabolism and of Ab deposition;
D=downstream mediator of APP or Ab; E =APP binding
partner. Asterisks indicate the genes reported to encode for APP
interacting proteins in the HPRD database and the genes
genetically linked to AD in the Alzgene database. The last column
(N) indicates the number of APP conserved coexpression lists in
which the corresponding gene was found. The genes are ranked by
decreasing N.
(PDF)
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